ArticleAsian Pacific journal of cancer prevention : APJCP2025
Prognostic Significance of Chaperonin-Containing Tailless Complex Polypeptide 6A (CCT6A) in Ewing Sarcoma.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChaperonin-Containing Tailless complex polypeptide 6A (CCT6A) is considered one of the biomarkers that play a role in cancer initiation, progression and resistance to body defenses and to anti-cancer drugs. Its exact prognostic role in Ewing sarcoma (ES) remains uncertain. The aim of this study is to assess immunohistochemical (IHC) expression of CCT6A in ES, and to assess the relation of its expression to different clinicopathological parameters and evaluate its prognostic significance in ES cases.
methodsThis retrospective cohort study included 35 cases diagnosed as ES at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt. Clinicopathological and survival data were collected. IHC for CCT6A was performed and correlated with clinicopathological parameters and patients' prognosis.
resultsHigh IHC expression of CCT6A was found in 28 cases out of the studied 35 ES cases (80%), while 7 cases only (20%) showed low CCT6A expression. High CCT6A expression showed significant association with tumor size ≥8 cm (P= 0.01), treatment with adjuvant radiotherapy either for local control, infiltrated surgical margins or poor histopathological response to chemotherapy (P= 0.01), poor histopathological response to chemotherapy (P= 0.02), and HUVOS grades I and II (P= 0.01). High CCT6A expression was found to be a predictor of shorter overall survival and was an independent poor predictive factor by multivariate analysis (P= 0.03).
conclusionHigh CCT6A expression in ES associates with large tumor size, treatment with adjuvant radiotherapy for aforementioned indications, poor histopathological response to chemotherapy, and HUVOS grades I and II. Its high expression also independently predicts poor overall survival in ES patients. It may be used as a useful biomarker to predict prognosis of ES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.